日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

The Road to Readiness: Commentary on the Journey of a Zoonotic H5 Influenza Vaccine Strain Update

迈向准备之路:人畜共患H5流感疫苗株最新进展评述

Kennedy, Alexander T; Longstaff, Ray; Fitzpatrick, James; Hughes, Clare; Malatesta, Maria Teresa; Brandi, Raffaella; Beighton, Joanne; Versage, Eve; Music, Nedzad; Xu, Howard; Pagni, Monica; Hohenboken, Matthew; Taylor, Beverly

Immunogenicity and safety of self-amplifying mRNA COVID-19 vaccine (ARCT-2303), with or without co-administration of seasonal inactivated influenza vaccine in adults: a phase 3, randomised, controlled, observer-blind, multicentre study

在成人中,接种或不接种季节性灭活流感疫苗的自扩增mRNA COVID-19疫苗(ARCT-2303)的免疫原性和安全性:一项3期随机、对照、观察者盲法、多中心研究

Giles, Michelle L; Tabora, Charissa; Baccarini, Carmen; Barrientos, Leonela; Vargas, Javier Cespedes; Montellano, May Emmeline; Nguyen, Paul; Deshmukh, Sachin; Neville, Munro; Hohenboken, Matthew; van Boxmeer, Josephine; Jin, Hongfan; Bugarini, Roberto; Liu, Xuexuan; Walson, Judd L; Verhoeven, Carole; Smolenov, Igor

Reactogenicity of an Inactivated, Split-Virion Quadrivalent Influenza Vaccine in Infants and Children Aged ≥6 Months to <9 Years

灭活裂解病毒四价流感疫苗在6个月至9岁以下婴幼儿中的反应原性

Nolan, Terry; Albano, Frank R; Oberije, Janine; Piedrahita, Maria; Hohenboken, Matthew

Safety, Tolerability, and Immunogenicity of aH5N1 Vaccine in Adults with and Without Underlying Immunosuppressive Conditions

H5N1疫苗在有或无潜在免疫抑制疾病的成人中的安全性、耐受性和免疫原性

Malfertheiner, Peter; Versage, Eve; Twuijver, Esther Van; Rizzardini, Giuliano; Hohenboken, Matthew

Safety, Tolerability, and Immunogenicity of aH5N1 Vaccine in Adults with and without Underlying Medical Conditions

H5N1疫苗在有或无基础疾病的成年人中的安全性、耐受性和免疫原性

Jelinek, Tomas; Schwarz, Tino F; Reisinger, Emil; Malfertheiner, Peter; Versage, Eve; Van Twuijver, Esther; Hohenboken, Matthew

Antibody responses against heterologous H5N1 strains for an MF59-adjuvanted cell culture-derived H5N1 (aH5n1c) influenza vaccine in adults and older adults

成人和老年人对MF59佐剂细胞培养衍生H5N1(aH5n1c)流感疫苗的异源H5N1毒株抗体反应

Frey, Sharon S; Versage, Eve; Van Twuijver, Esther; Hohenboken, Matthew

Immunogenicity and Safety of MF59-Adjuvanted Quadrivalent Influenza Vaccine Compared with a Nonadjuvanted, Quadrivalent Influenza Vaccine in Adults 50-64 Years of Age

在50-64岁成人中,MF59佐剂四价流感疫苗与非佐剂四价流感疫苗的免疫原性和安全性比较

Poder, Airi; Oberije, Janine; Meyer, Jay; Heymer, Peter; Molrine, Deborah; Versage, Eve; Isakov, Leah; Zhang, Qiuhong; Hohenboken, Matthew

Outcomes in Pregnant Persons Immunized with a Cell-Based Quadrivalent Inactivated Influenza Vaccine: A Prospective Observational Cohort Study

接种细胞培养四价灭活流感疫苗的孕妇的结局:一项前瞻性观察队列研究

Robinson, Christopher; Van Boxmeer, Josephine; Tilson, Hugh; Scialli, Anthony; Vanchiere, John A; Ides, Ellis; Sawlwin, Daphne; Molrine, Deborah; Hohenboken, Matthew; Edelman, Jonathan; Albano, Jessica D

Phase 3 Randomized, Multicenter, Placebo-Controlled Study to Evaluate Safety, Immunogenicity, and Lot-to-Lot Consistency of an Adjuvanted Cell Culture-Derived, H5N1 Subunit Influenza Virus Vaccine in Healthy Adult Subjects

一项评估佐剂细胞培养衍生H5N1亚单位流感病毒疫苗在健康成年受试者中安全性、免疫原性和批间一致性的3期随机、多中心、安慰剂对照研究

Peterson, James; Van Twuijver, Esther; Versage, Eve; Hohenboken, Matthew

Safety and Immunogenicity of MF59-Adjuvanted Cell Culture-Derived A/H5N1 Subunit Influenza Virus Vaccine: Dose-Finding Clinical Trials in Adults and the Elderly

MF59佐剂细胞培养衍生A/H5N1亚单位流感病毒疫苗的安全性和免疫原性:成人和老年人剂量探索临床试验

Frey, Sharon E; Shakib, Sepehr; Chanthavanich, Pornthep; Richmond, Peter; Smith, Timothy; Tantawichien, Terapong; Kittel, Claudia; Jaehnig, Peter; Mojares, Zenaida; Verma, Bikash; Kanesa-Thasan, Niranjan; Hohenboken, Matthew